| Paul George Sampson, | |
|
620 Birch St, Wakefield, KS 67487-9032 | |
| (785) 226-1445 | |
| Not Available |
| Full Name | Paul George Sampson |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 620 Birch St, Wakefield, Kansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043829104 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PH19390 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Paul George Sampson, 600 Caisson Hill Rd, Ft Riley, KS 66442-7037 Ph: () - | Paul George Sampson, 620 Birch St, Wakefield, KS 67487-9032 Ph: (785) 226-1445 |
News Archive
Tahitian Noni International announced that the first annual International Iridoid Research Symposium will be held at TNI headquarters in Provo, Utah, on August 16th and 17th. Scientists from around the world will be presenting current research on iridoids in both plants and animals. The symposium is being presented by the International Iridoid Research Council, which is a new organization dedicated to the sharing of information and research being conducted on iridoids.
A Rhode Island Hospital researcher has found that the use of electronic prescription drug monitoring programs (PMPs) may have a significant impact on the demand for drug treatment programs and how prescribers detect and respond to abuse of painkillers.
Activaero GmbH, a technology leader in controlled breathing inhalation devices, today announced that it has closed a further financing round of € 5.0 million.
Novartis Pharmaceuticals Corporation announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3, was presented at the 12th World Congress on Gastrointestinal Cancer and is part of the largest clinical trial program in patients with advanced NET.
As a heart fails, losing its ability to squeeze blood through the circulatory system, the body releases a neurohormone that interferes with the heart's best chance to improve contractility, a team of Temple University School of Medicine researchers show in a study published September 9th in the American Heart Association journal, Circulation.
› Verified 1 days ago